Commitments and contingencies - Additional Information (Details) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Nov. 15, 2021 |
Jan. 31, 2020 |
Sep. 30, 2020 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Commitments And Contingencies [Line Items] | |||||
| Issuance of common stock, net of issuance costs | $ 61,681,000 | $ 74,352,000 | |||
| License Agreement | Kayla Therapeutics S.A.S | |||||
| Commitments And Contingencies [Line Items] | |||||
| Nonrefundable payment in cash | $ 15,000,000.0 | ||||
| Nonrefundable payment in shares of common stock | 177,318 | ||||
| Nonrefundable cash payment paid | $ 15,000,000.0 | ||||
| MD Anderson Cancer Center | Research Agreement | Series B Redeemable Convertible Preferred Stock | |||||
| Commitments And Contingencies [Line Items] | |||||
| Issuance of common stock, net of issuance costs | $ 1,200,000 | ||||
| Lonza | Manufacturing Services Agreement | |||||
| Commitments And Contingencies [Line Items] | |||||
| Cancellation fees and other charges | 0 | ||||
| Minimum non-cancelable purchase obligation | $ 0 | ||||
| Agreement termination advance notice period | 12 months | ||||